Rudy Li Analyst PerformanceAnalyst at Wolfe ResearchRudy Li is a stock analyst at Wolfe Research in the medical sector, covering 16 publicly traded companies. Over the past year, Rudy Li has issued 45 stock ratings, including strong buy, buy, and hold recommendations. While full access to Rudy Li's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Rudy Li's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings50 Last 3 YearsBuy Recommendations94.00% 47 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution50RatingsDistribution of strong buy, buy, hold, and sell ratings by Rudy Li.RatingPercentageCount Strong Buy22.0%11 ratings Buy72.0%36 ratings Hold6.0%3 ratings Sell0.0%0 ratingsOut of 50 total stock ratings issued by Rudy Li at Wolfe Research, the majority (72.0%) have been Buy recommendations, followed by 22.0% Strong Buy and 6.0% Hold.Best & Worst CallsBest Call0000.0%PRAXMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%STOKOct 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ93.8% of companies on NASDAQ15 companiesNYSE6.3% of companies on NYSE1 companyRudy Li, an analyst at Wolfe Research, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical16 companies100.0%Rudy Li of Wolfe Research specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE12 companies75.0%MED - DRUGS3 companies18.8%BIOTECHNOLOGY1 company6.3% Rudy Li's Ratings History at Wolfe Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCNTACentessa Pharmaceuticals3/31/2026Downgrade$39.97Hold$0.0000.00% ROICNTACentessa Pharmaceuticals2/24/2026Initiated Coverage$25.49$40.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences2/24/2026Initiated Coverage$128.38$160.00Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals2/23/2026Initiated Coverage$24.73$33.00Outperform$0.0000.00% ROIDFTXDefinium Therapeutics2/23/2026Initiated Coverage$16.95$25.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines2/23/2026Initiated Coverage$342.46$500.00Outperform$0.0000.00% ROIDNLIDenali Therapeutics2/23/2026Initiated Coverage$20.86Peer Perform$0.0000.00% ROIQUREuniQure2/23/2026Initiated Coverage$24.47Peer Perform$0.0000.00% ROISTOKStoke Therapeutics2/23/2026Initiated Coverage$36.23$40.00Outperform$0.0000.00% ROIXENEXenon Pharmaceuticals2/23/2026Initiated Coverage$42.72$60.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. AXSMAxsome Therapeutics2/23/2026Initiated Coverage$174.76$230.00Outperform$0.0000.00% ROIALKSAlkermes2/23/2026Initiated Coverage$32.19$45.00Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals2/23/2026Initiated Coverage$24.59$33.00Outperform$0.0000.00% ROIALKSAlkermes2/23/2026Initiated Coverage$33.39$45.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics2/23/2026Initiated Coverage$169.95$230.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals2/23/2026Upgrade$26.52Strong-Buy$0.0000.00% ROIDFTXDefinium Therapeutics2/23/2026Initiated Coverage$17.45$25.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences2/23/2026Upgrade$130.96Strong-Buy$0.0000.00% ROIPRAXPraxis Precision Medicines2/23/2026Initiated Coverage$342.71$500.00Outperform$0.0000.00% ROISTOKStoke Therapeutics2/23/2026Initiated Coverage$35.50$40.00Outperform$0.0000.00% ROIXENEXenon Pharmaceuticals2/23/2026Initiated Coverage$44.79$60.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals1/2/2026Reiterated Rating$25.01$30.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences1/2/2026Reiterated Rating$78.04$80.00Buy$0.0000.00% ROIANROAlto Neuroscience11/19/2025Upgrade$14.19Strong-Buy$0.0000.00% ROICNTACentessa Pharmaceuticals11/19/2025Upgrade$27.54Strong-Buy$0.0000.00% ROIIMUXImmunic11/19/2025Upgrade$0.69Strong-Buy$0.0000.00% ROIDFTXDefinium Therapeutics11/19/2025Upgrade$10.88Strong-Buy$0.0000.00% ROIPRAXPraxis Precision Medicines11/19/2025Upgrade$164.09Strong-Buy$0.0000.00% ROIPRTAProthena11/19/2025Upgrade$10.05Strong-Buy$0.0000.00% ROIRVPHReviva Pharmaceuticals11/19/2025Upgrade$0.48Strong-Buy$0.0000.00% ROISTOKStoke Therapeutics11/19/2025Upgrade$27.93Strong-Buy$0.0000.00% ROIXENEXenon Pharmaceuticals11/19/2025Upgrade$40.27Strong-Buy$0.0000.00% ROIPRAXPraxis Precision Medicines10/17/2025Set Price Target$162.71$330.00Buy$0.0000.00% ROIXENEXenon Pharmaceuticals10/7/2025Reiterated Rating$39.55$55.00Buy$0.0000.00% ROIIMUXImmunic9/29/2025Initiated Coverage$9.39$130.00Buy$0.0000.00% ROIANROAlto Neuroscience9/29/2025Initiated Coverage$3.95$15.00Buy$0.0000.00% ROIRVPHReviva Pharmaceuticals9/29/2025Initiated Coverage$5.90$40.00Buy$0.0000.00% ROIPRTAProthena8/28/2025Reiterated Rating$8.56$18.00Buy$0.0000.00% ROISTOKStoke Therapeutics8/13/2025Reiterated Rating$16.44$24.00Buy$0.0000.00% ROIXENEXenon Pharmaceuticals8/12/2025Reiterated Rating$35.99$55.00Buy$0.0000.00% ROIBefore you buy SpaceX shares, consider this alternative approach (Ad)SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.Discover the overlooked SpaceX IPO strategy before the June listingCNTACentessa Pharmaceuticals8/12/2025Reiterated Rating$17.11$30.00Buy$0.0000.00% ROIPRTAProthena8/5/2025Reiterated Rating$6.94$18.00Buy$0.0000.00% ROIDFTXDefinium Therapeutics8/1/2025Reiterated Rating$9.09$20.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals7/30/2025Reiterated Rating$16.56$30.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines7/29/2025Reiterated Rating$55.65$80.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals5/8/2025Initiated Coverage$12.08$30.00Buy$00.0000.00% ROIXENEXenon Pharmaceuticals5/7/2025Initiated Coverage$35.18$55.00Buy$00.0000.00% ROIPRAXPraxis Precision Medicines5/7/2025Initiated Coverage$35.17$80.00Buy$000.0000.00% ROIDRUGBright Minds Biosciences5/7/2025Initiated Coverage$29.40$80.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
